Researchers have revealed that a drug created from the shark cartilage failed in providing any relief to the cancer patients in advanced lung cancer stages. The researchers also found that, drug couldn't even extend the life of the cancer patients with untreatable stage III non-small cell lung cancer.
Shark cartilage has long been considered as a chief complementary cancer treatment by the scientists.
The drug seemed to be useful initially in preventing the growth of blood vessels around the tumors. It was expected to prove helpful in preventing the cancer cells from receiving more blood which boosts their growth.
The lead researcher Dr. Charles Lu, of the University of Texas M. D. Anderson Cancer Center, examined the drug on the basis of AE-941 on the US and Canadian patients.
It was published online in the Journal of the National Cancer Institute on May 26.
Almost 379 patients with inoperable non-small cell lung cancer were given a chemoradiotherapy treatment or AE-941, under the study. No specific differences were found in the results from the top categories.
"The study's impetus was the widespread use of poorly regulated complementary and alternative medicine products, such as shark cartilage-derived agents, among patients with advanced cancer", quoted the researchers.